Bengaluru-based Neuralzome Cybernetics has raised $2.4 million in a new funding round, marking another vote of confidence in India’s growing deeptech and neurotech ecosystem. The round was backed by a mix of domestic and international investors, aiming to help the startup move faster from lab prototypes to real-world products.
What Neuralzome builds
Neuralzome focuses on advanced neurotechnology solutions that combine brain-inspired computing and precision sensing. The startup’s work targets applications in healthcare, assistive devices, robotics and industrial automation. By blending hardware and software, Neuralzome aims to create low-power, high-performance systems that can interact with biological signals and complex environments.
How the funds will be used
The freshly raised capital will be deployed to:
- Expand R&D and accelerate product development
- Hire talent in engineering and clinical partnerships
- Set up testing and prototyping facilities in India
- Strengthen go-to-market efforts and pilot programmes with hospitals and industries
These steps are expected to shorten the route from prototypes to pilots, especially in clinical and assistive technology use cases where strong regulatory and clinical validation are needed.
Why this matters for India
India is seeing more investments into deeptech startups that require long development cycles and specialized talent. Neuralzome’s round highlights a growing appetite among investors for neurotech that can solve local and global challenges.
For patients and clinicians, home-grown neurotech can mean more affordable and locally adapted solutions. For India’s startup ecosystem, it underlines Bengaluru and other tech hubs as centres not just for software, but for cutting-edge hardware and biomedical innovation.
The road ahead
Neuralzome plans to collaborate with research institutes, hospitals and manufacturing partners across India. The company is also likely to target international markets once initial clinical validations and regulatory approvals are in place.
This raise comes at a time when Indian startups are increasingly moving up the value chain—from app-first plays to capital-intensive, science-driven ventures. Neuralzome’s progress will be watched closely by investors, clinicians and technologists eager to see Indian neurotech make a global impact.